PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Hisham Shiblaq Sells 247 Shares

PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Hisham Shiblaq sold 247 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $14,093.82. Following the sale, the executive vice president now directly owns 63,133 shares of the company’s stock, valued at approximately $3,602,368.98. This represents a 0.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

PROCEPT BioRobotics Trading Up 1.4 %

Shares of PRCT stock opened at $57.80 on Thursday. The stock has a market cap of $3.17 billion, a price-to-earnings ratio of -29.64 and a beta of 1.05. PROCEPT BioRobotics Co. has a twelve month low of $45.56 and a twelve month high of $103.81. The company’s 50-day moving average price is $68.87 and its 200-day moving average price is $78.75. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The company had revenue of $68.24 million during the quarter, compared to analysts’ expectations of $66.79 million. As a group, equities analysts predict that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on PRCT. Truist Financial restated a “buy” rating and set a $90.00 target price (down previously from $105.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, February 26th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $112.00 price target on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. Finally, Morgan Stanley cut their target price on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $94.29.

Hedge Funds Weigh In On PROCEPT BioRobotics

Large investors have recently bought and sold shares of the company. Principal Financial Group Inc. boosted its position in PROCEPT BioRobotics by 290.2% during the third quarter. Principal Financial Group Inc. now owns 68,617 shares of the company’s stock worth $5,498,000 after purchasing an additional 51,030 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new position in PROCEPT BioRobotics during the 3rd quarter worth $842,000. KBC Group NV raised its position in shares of PROCEPT BioRobotics by 32.6% during the 3rd quarter. KBC Group NV now owns 1,531 shares of the company’s stock worth $123,000 after purchasing an additional 376 shares during the period. Swiss National Bank increased its holdings in shares of PROCEPT BioRobotics by 5.8% during the third quarter. Swiss National Bank now owns 95,400 shares of the company’s stock valued at $7,643,000 after purchasing an additional 5,200 shares during the period. Finally, LMR Partners LLP lifted its position in PROCEPT BioRobotics by 63.5% in the third quarter. LMR Partners LLP now owns 23,361 shares of the company’s stock worth $1,872,000 after purchasing an additional 9,072 shares during the period. Hedge funds and other institutional investors own 89.46% of the company’s stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).